+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Colitis - Pipeline Review, H1 2019

  • ID: 4750093
  • Drug Pipelines
  • 117 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AlfaSigma SpA
  • Dr. Falk Pharma GmbH
  • Genfit SA
  • Immuron Ltd
  • Nippon Kayaku Co Ltd
  • Principia Biopharma Inc
  • MORE
Colitis - Pipeline Review, H1 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Colitis - Pipeline Review, H1 2019, provides an overview of the Colitis (Gastrointestinal) pipeline landscape.

Colitis is swelling (inflammation) of the large intestine (colon). Colitis can have many different causes, including infections, including those caused by a virus, parasite, and food poisoning due to bacteria, inflammatory disorders (ulcerative colitis and Crohn's disease), lack of blood flow (ischemic colitis), past radiation to the large bowel). Symptoms can include abdominal pain, bloating, bloody stools, chills, dehydration, diarrhea and fever. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.

Report Highlights

This latest pipeline guide Colitis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 24, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 7 molecules, respectively.

Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Colitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Colitis (Gastrointestinal)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Colitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AlfaSigma SpA
  • Dr. Falk Pharma GmbH
  • Genfit SA
  • Immuron Ltd
  • Nippon Kayaku Co Ltd
  • Principia Biopharma Inc
  • MORE
Introduction

Colitis - Overview

Colitis - Therapeutics Development

Colitis - Therapeutics Assessment

Colitis - Companies Involved in Therapeutics Development

Colitis - Drug Profiles

Colitis - Dormant Projects

Colitis - Discontinued Products

Colitis - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Colitis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Colitis - Pipeline by AlfaSigma SpA, H1 2019

Colitis - Pipeline by Apollo Endosurgery Inc, H1 2019

Colitis - Pipeline by Concenter BioPharma Silkim Ltd, H1 2019

Colitis - Pipeline by Dr. Falk Pharma GmbH, H1 2019

Colitis - Pipeline by enGene Inc, H1 2019

Colitis - Pipeline by Genfit SA, H1 2019

Colitis - Pipeline by Handa Pharmaceuticals LLC, H1 2019

Colitis - Pipeline by Immodulon Therapeutics Ltd, H1 2019

Colitis - Pipeline by Immuron Ltd, H1 2019

Colitis - Pipeline by Inflazome Ltd, H1 2019

Colitis - Pipeline by Nippon Kayaku Co Ltd, H1 2019

Colitis - Pipeline by Ogeda SA, H1 2019

Colitis - Pipeline by Principia Biopharma Inc, H1 2019

Colitis - Pipeline by Protagonist Therapeutics Inc, H1 2019

Colitis - Pipeline by RDD Pharma Ltd, H1 2019

Colitis - Pipeline by Saniona AB, H1 2019

Colitis - Pipeline by Scholar Rock Inc, H1 2019

Colitis - Pipeline by Soligenix Inc, H1 2019

Colitis - Pipeline by Synthetic Biologics Inc, H1 2019

Colitis - Pipeline by Vitality Biopharma Inc, H1 2019

Colitis - Dormant Projects, H1 2019

Colitis - Dormant Projects, H1 2019 (Contd..1), H1 2019

Colitis - Dormant Projects, H1 2019 (Contd..2), H1 2019

Colitis - Discontinued Products, H1 2019

List of Figures

Number of Products under Development for Colitis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AlfaSigma SpA
  • Apollo Endosurgery Inc
  • Concenter BioPharma Silkim Ltd
  • Dr. Falk Pharma GmbH
  • enGene Inc
  • Genfit SA
  • Handa Pharmaceuticals LLC
  • Immodulon Therapeutics Ltd
  • Immuron Ltd
  • Inflazome Ltd
  • Nippon Kayaku Co Ltd
  • Ogeda SA
  • Principia Biopharma Inc
  • Protagonist Therapeutics Inc
  • RDD Pharma Ltd
  • Saniona AB
  • Scholar Rock Inc
  • Soligenix Inc
  • Synthetic Biologics Inc
  • Vitality Biopharma Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4750093
Adroll
adroll